AstraZeneca PLC (AZN.L) Earnings
Price: $11316.00
Market Cap: $175.47B
Market Cap: $175.47B
Revenue (TTM): $54.07B
Net Income: $7.04B
Net Income: $7.04B
P/E Ratio: 32.34
EPS (TTM): $4.53
EPS (TTM): $4.53
Earnings Dates
AstraZeneca PLC (AZN.L) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: April 29, 2025
- Time of Day: Before Market Open
- Estimated EPS: $2.19
Last Earnings Report
- Date: February 06, 2025
- EPS: $2.09
- EPS Estimate: $2.07
AstraZeneca PLC's next earnings report is scheduled for April 29, 2025.
In its last earnings report on February 06, 2025, AstraZeneca PLC reported earnings per share (EPS) of $2.09, compared to an estimated EPS of $2.07. The company reported revenue of $11.90B, compared to an estimated revenue of $14.23B.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-06 | $2.07 | $2.09 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $1.49 | $2.08 |
| Read Transcript | Q2 | 2024 | 2024-07-25 | $1.96 | $1.98 |
| Read Transcript | Q1 | 2024 | 2024-04-25 | $1.91 | $2.06 |
| Read Transcript | Q4 | 2023 | 2024-02-08 | $1.49 | $1.45 |
| Read Transcript | Q3 | 2023 | 2023-11-09 | $1.62 | $1.73 |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| February 06, 2025 | $2.09 | $2.07 | $11.90B | $14.23B |
| November 12, 2024 | $2.08 | $1.49 | $13.56B | $13.08B |
| July 25, 2024 | $1.98 | $1.96 | $12.94B | $12.62B |
| April 25, 2024 | $2.06 | $1.91 | $12.68B | $11.80B |
| February 08, 2024 | $1.45 | $1.49 | $12.02B | $9.53B |
| November 09, 2023 | $1.73 | $1.62 | $11.49B | $9.50B |
| July 28, 2023 | $2.15 | $1.95 | $11.42B | $9.02B |
| April 27, 2023 | $1.92 | $1.71 | $10.88B | $8.60B |
| February 09, 2023 | $1.38 | $1.29 | $11.21B | $9.30B |
| November 10, 2022 | $1.67 | $1.52 | $10.98B | $9.67B |
| July 29, 2022 | $1.72 | $1.56 | $10.77B | $8.59B |
| April 29, 2022 | $1.89 | $1.69 | $11.39B | $8.23B |
| February 10, 2022 | $1.67 | $1.50 | $12.01B | $8.22B |
| November 12, 2021 | $1.08 | $1.28 | $9.87B | $- |
| July 29, 2021 | $0.90 | $0.90 | $8.22B | $- |
| April 30, 2021 | $1.63 | $1.48 | $7.32B | $- |
| February 11, 2021 | $1.07 | $1.20 | $7.41B | $- |
Annual Earnings
Annual Revenue
$54.07B
Fiscal Year 2024Annual Net Income
$7.04B
Fiscal Year 2024Annual EPS
$4.53
Fiscal Year 2024Quarterly Earnings
Revenue
$14.89B
Quarter Ending December 31, 2024Net Income
$1.50B
Quarter Ending December 31, 2024EPS
$0.97
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
3.46%
Year Ending December 31, 2024P/E Ratio
28.93
Year Ending December 31, 2024Revenue Per Share
$34.80
Year Ending December 31, 2024Earnings Yield (TTM)
3.09%
Trailing Twelve MonthsP/E Ratio (TTM)
32.34
Trailing Twelve MonthsRevenue Per Share (TTM)
$34.80
Trailing Twelve MonthsFrequently Asked Questions
AstraZeneca PLC's next earnings date is scheduled for April 29, 2025. The earnings call is expected to take place before market open.
In its last earnings report on February 06, 2025, AstraZeneca PLC reported earnings per share (EPS) of $2.09, compared to an estimated EPS of $2.07. The company reported revenue of $11.90B, compared to an estimated revenue of $14.23B.
AstraZeneca PLC's current Price-to-Earnings (P/E) ratio is 28.93. The trailing twelve months (TTM) P/E ratio is 32.34. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, AstraZeneca PLC reported total revenue of $54.07B and net income of $7.04B. This represents a net profit margin of 0.1301018993.
AstraZeneca PLC's earnings yield is 3.46%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
AstraZeneca PLC's return on equity (ROE) is 17.25%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
AstraZeneca PLC's gross profit margin is 81.12%. This indicates that for every dollar of revenue, the company retains $0.81 as gross profit after accounting for the cost of goods sold.
Related Metrics
Explore detailed financial metrics and analysis for AZN.L.